TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06573749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bioactive whey protein concentrate
Description: Every day for 12 weeks, participants will mix 1 pre-packaged sachet with \~350ml of water and consume the resultant drink alongside their breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pea-based protein supplement
Description: Every day for 12 weeks, participants will mix 1 pre-packaged sachet with \~350ml of water and consume the resultant drink alongside their breakfast.
Study: NCT03762135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full version of the LIITah App.
Description: Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partial App. (ELI and SNAP only)
Description: Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
Study: NCT05181605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox and Stereotactic Body Radiotherapy
Description: Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
Study: NCT05468840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: see study arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: see study arm description
Study: NCT06315621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scanning using intraoral scanner with markers
Description: Scanning different types of nasal defects using intraoral scanner with skin markers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scanning using intraoral scanner without markers
Description: Scanning different types of nasal defects using intraoral scanner without skin markers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Impression
Description: Recording different types of nasal defects using physical impressions
Study: NCT04410627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HoPE Website
Description: Educational website focused on hospice care
Study: NCT06422832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HeartLogic or TriageHF Algorithms for implantable devices
Description: Activation of the HeartLogic and TriageHF algorithms for implantable devices and correctly act according to its design
Study: NCT05406622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOTIV Sirolimus-Eluting Bioresorbable Scaffold
Description: Participants will receive the MOTIV device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA) Device
Description: Participants will receive PTA treatment
Study: NCT06286813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant (natural) oils
Description: Using 10 ml of plant(natural) oil once a day for daily skin care of newborns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant (natural) oils
Description: Using 10 ml of plant(natural) oil once a day for daily skin care of newborns
Study: NCT05940467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Loss
Description: Participants will undergo periods of sleep loss in a laboratory setting and be monitored hourly for changes in indicators of arterial stiffness (i.e., pulse wave velocity).
Study: NCT05804201

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob
Description: (2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
Study: NCT05302700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Parental Sensitivity Intervention
Description: Parental sensitivity intervention include (1)Establish an emotional connection：Using the VR tour to introduce the environment, instruments and equipment of the neonatal intensive care unit, appearance of premature infants and pipeline wires on their bodies .(2)maintain physical proximity:proactively provide mothers with the opportunity to touch the body of preterm infants.(3) parents must understand their infant's cues:Using the Premature Infant Behavioral Clues Teaching Materials to play video and we will discuss and respond to the mother's questions.(4)engage in his/her care and communicate appropriately with him/her:We will discuss the behavioral clues of the preterm infant with the mother next to the incubator, encourage the mother to ask questions and participate in care activities such as changing diapers and stamping the baby's footprints on the card, asking the mother to write down the number of days of birth, corrected age, weight and what she wants to say for her baby.
Study: NCT05660837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T1: Mixed mode social support group
Description: This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program~1. In person get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. In-person baking class x 1 session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T2: Online mode social support group
Description: This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.~1. Online get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. Online baking class x 1 session through WhatsApp
Study: NCT06354439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: 10 mg of letrozole PO for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate Sodium
Description: 100 mg of methotrexate IM, single dose
Study: NCT06536946

Intervention type: BIOLOGICAL
Intervention: Immunohistochemical staining
Description: Staining of cutanous squamous cell carcinoma and its mimickers by monoclonal antibodies against human B-catenin by immunohistochemical procedures
Study: NCT05207176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
Study: NCT05070897

Intervention type: OTHER
Intervention: Questionnaires
Description: * Approved French version of the FCCHL scale~* Questionnaire on the use of digital tools adapted from the questionnaire on digital tools

Intervention type: OTHER
Intervention: Questionnaires
Description: * Approved French version of the FCCHL scale~* Questionnaire on the use of digital tools adapted from the questionnaire on digital tools
Study: NCT05091567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Study: NCT04923607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731
Description: TQC2731 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731
Description: TQC2731 injection
Study: NCT06582355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The participants will be instructed to use cognitive strategies to upregulate (increase) their brain activity in the selected brain region, with the suggestion that motor imagery may be particularly effective, for example, mental imagery of swimming or playing a musical instrument. During the rest blocks, the participants will be instructed to relax. The instructions to start and stop the regulation and rest blocks are visualized on a screen in the scanner, and the brain activity of the putamen will be displayed in real-time using a thermometer bar for visualization.
Study: NCT04923607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731
Description: TQC2731 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo with no active ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo with no active ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo with no active ingredients
Study: NCT04474522

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Preimplantation genetic testing for aneuploidy status
Description: In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
Study: NCT02786277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alert
Description: An alert informing the provider of the presence of acute kidney injury will be fired.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alert
Description: An alert informing the provider of the presence of acute kidney injury will be fired.
Study: NCT03819296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care
Study: NCT06582355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesthetic imagery
Description: The participants will be instructed to imagine movements during the active blocks. During the rest blocks, the participants will be instructed to relax. The instructions to start and stop the regulation and rest blocks are visualized on a screen in the scanner. No feedback is provided regarding brain activity.
Study: NCT06111417

Intervention type: OTHER
Intervention: Questionnaires
Description: 3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~* STAI-Y (State-Trait Anxiety Inventory)~* Patient's Questionnaire~* Practitioner's questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: 3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~* STAI-Y (State-Trait Anxiety Inventory)~* Patient's Questionnaire~* Practitioner's questionnaire

Intervention type: OTHER
Intervention: Communication of the results of the BRCA1/2 ultra rapid test
Description: Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
Study: NCT04980391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT
Description: Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
Study: NCT05801107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-0593
Description: WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
Study: NCT05688527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleansing Balm
Description: DermResults Cleansing Balm w/ Avocado Oil twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toning Essence
Description: DermResults Advanced Toning Essence w/ Mineral Booster twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Serum
Description: DermResults Advanced Serum w/ Hyaluronic Acid twice daily
Study: NCT05489094

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education and Growing Up Milk for 1 - 3 years old
Description: Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Education
Description: Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
Study: NCT04932174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity Interval Training
Description: Consisting of the following program:~* Warming up period for 10 minutes at 60-70% of HR max.~* Training phase 4x4 min intervals at 85-90% of HRmax with a 3 min active recovery at 70% of HRmax between each interval.~* Duration of HIIT 4 minute~* Number of interval per session 4~* Duration of rest interval 3 minute 3-10 min cool-down period, giving a total of 60 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity Continuous Training
Description: Consisting of the following program:~* Warming up period for 10 minutes.~* Training phase for 60-minute walking on a treadmill at intensity 40-50% HRR (1- 6) weeks then 60-70% HRR (7-12) weeks.~* cooling down period for 10 minutes.
Study: NCT04905680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM lifestyle tracking and coaching
Description: Participants in the experimental group will go through a total of 5 lifestyle tracking sessions (including baseline), of which 1 will include CGM tracking. For this CGM lifestyle tracking session, experimental group participants will receive real-time feedback through the study applications, which will display the CGM trace.~The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans.
Study: NCT05916755

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Genome Sequencing
Description: Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Genome Sequencing
Description: Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.

Intervention type: DIAGNOSTIC_TEST
Intervention: RNA-Sequencing
Description: RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).

Intervention type: DIAGNOSTIC_TEST
Intervention: RNA-Sequencing
Description: RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analysis
Description: Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analysis
Description: Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA analysis
Description: ctDNA analysis will be performed in plasma before and during NACT.

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA analysis
Description: ctDNA analysis will be performed in plasma before and during NACT.

Intervention type: DIAGNOSTIC_TEST
Intervention: TCR-β repertoire sequencing
Description: TCR-β repertoire sequencing will be performed in plasma before and during NACT.

Intervention type: DIAGNOSTIC_TEST
Intervention: TCR-β repertoire sequencing
Description: TCR-β repertoire sequencing will be performed in plasma before and during NACT.
Study: NCT05688527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Cream
Description: DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
Study: NCT05916755

Intervention type: DIAGNOSTIC_TEST
Intervention: PBMCs phenotyping
Description: PBMCs phenotyping will be performed in plasma before and during NACT.

Intervention type: DIAGNOSTIC_TEST
Intervention: PBMCs phenotyping
Description: PBMCs phenotyping will be performed in plasma before and during NACT.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Pembrolizumab will be given in combination with standard NACT.

Intervention type: DRUG
Intervention: Chemotherapy
Description: Standard NACT will be given.

Intervention type: DRUG
Intervention: Chemotherapy
Description: Standard NACT will be given.
Study: NCT05345691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bmab 1000
Description: 60 mg administered as a single SC (subcutaneous) injection once every 6 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: 60 mg administered as a single SC injection once every 6 months
Study: NCT03819296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of stool, blood, and tissue samples
Study: NCT05063734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 dose level 1
Description: 3 intravitreal injections of THR-687 dose level 1, 1 month apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 dose level 2
Description: 3 intravitreal injections of THR-687 dose level 2, 1 month apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 selected dose level
Description: 3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 selected dose level
Description: 3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
Study: NCT03819296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Given intravenously (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Given IV
Study: NCT05489068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing at Intake (MII)
Description: The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intake as Usual (IAU)
Description: In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.